Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 86.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 174,397 shares of the biopharmaceutical company’s stock after selling 1,083,811 shares during the period. Victory Capital Management Inc. owned approximately 0.06% of Amicus Therapeutics worth $1,643,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its position in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after purchasing an additional 2,856,101 shares during the period. Geode Capital Management LLC grew its position in Amicus Therapeutics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock worth $70,499,000 after purchasing an additional 80,926 shares during the period. Massachusetts Financial Services Co. MA grew its position in Amicus Therapeutics by 4.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock worth $33,749,000 after purchasing an additional 139,491 shares during the period. Charles Schwab Investment Management Inc. grew its position in Amicus Therapeutics by 10.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after purchasing an additional 242,672 shares during the period. Finally, Rice Hall James & Associates LLC grew its position in Amicus Therapeutics by 41.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock worth $12,916,000 after purchasing an additional 398,942 shares during the period.

Amicus Therapeutics Trading Down 1.5 %

FOLD stock opened at $8.98 on Wednesday. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 12-month low of $8.55 and a 12-month high of $12.65. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -49.89, a PEG ratio of 1.51 and a beta of 0.69. The business’s 50-day moving average is $9.36 and its 200 day moving average is $10.11.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Wells Fargo & Company dropped their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.